Dr. Oleg Gligich, MD

Dr. Gligich practices at Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida.

Dr. Gligich's NPI, 1215224126, was assigned on June 30, 2011. Dr. Gligich holds Florida license ME 131522.

Dr. Gligich's primary practice is Mount Sinai Medical Center, at 4300 Alton Rd, Miami Beach, FL 33140 in Miami-Dade County. The practice phone is (305) 674-2121.

Dr. Gligich's primary practice is Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida. The medical group on file is Mount Sinai Medical Center. Dmand AI also links Dr. Gligich to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gligich practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gligich's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gligich is licensed in Florida.

CMS data shows 1,446 Medicare services from Dr. Gligich across 7 procedure codes in 2024, for 320 Medicare patients. Medicare paid $67,144 for them.

CMS counts 320 Medicare patients who saw Dr. Gligich in 2024. The largest group is 75 to 84, with 129 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gligich's median patient age at 74, with 52% women.

In 2024, Dr. Gligich wrote 2,553 Medicare Part D claims for 394 patients. 61% of them were for generic drugs. CMS names the drug for 2,211 of them, across 47 drugs with 11 or more claims each, at $12,361,031 in total drug cost. In 2023, CMS named 1,756 claims across 48 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Gligich for performance year 2024, reported through an alternative payment model (APM). Dr. Gligich accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gligich as offering telehealth.

Dmand AI links 7 papers to Dr. Gligich, published from 2013 to 2022. 2013 was the busiest year, with 2. The most frequent topics are HIV Infections, Coinfection and Hematologic Neoplasms. Dr. Gligich's most frequent co-authors are Henny H. Billett, MD, Radha V. Raghupathy, MD and Steven R. Abram, MD.

Dmand AI links Dr. Gligich to 4 clinical trials, 2 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Lung Neoplasms and Urachal adenocarcinoma. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 1,463 general payments to Dr. Gligich from 81 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 56% of the total. AstraZeneca Pharmaceuticals LP paid the most, $7,710.